Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are consistent with improved glucose control and significant weight loss. But GLP-1RAs may also have additive benefits by improving postprandial dysmetabolism. In diabetes, dysregulated postprandial nutrient excursions trigger inflammation, oxidative stress, endothelial dysfunction, thrombogenicity, and endotoxemia; alter hormone levels; and modulate cardiac output and regional blood and lymphatic flow. In this perspective, we explore the actions of GLP-1RAs on the postprandial state and their potential role in end-organ benefits observed in recent trials.
Keywords: GLP-1 receptor; GLP-1 receptor agonist; cardioprotection; cardiovascular outcomes; diabetic complications; glucagon-like peptide-1; major acute cardiovascular event; renoprotection; type 2 diabetes.
Copyright © 2023 Elsevier Inc. All rights reserved.